(redirected from High-Grade Cervical Intraepithelial Neoplasia)
HGCINHigh-Grade Cervical Intraepithelial Neoplasia (human papillomavirus)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
To analyze the effectiveness of gene methylation for triage of high-grade cervical intraepithelial neoplasia, individuals were recategorized into normal tissue, CIN1, and CIN2+ (CIN2-3) subgroups.
Berkhof et al., "Riskof recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study," The Lancet Oncol ogy, vol.
Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities.
Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study.
(3-6) When a hysterectomy has been performed because of a diagnosis of high-grade cervical intraepithelial neoplasia, up to 7.4% of patients have been reported to develop subsequent vaginal intraepithelial neoplasia (VAIN).
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.
Routine cytology testing should be discontinued after total hysterectomy for benign indications, provided the woman has no history of high-grade cervical intraepithelial neoplasia or adenocarcinoma in situ.
In particular, cohort studies have shown that infection with HPV-16 or with high-risk HPVs as a class occurs before the development of high-grade cervical intraepithelial neoplasia, which is thought to be a precursor of invasive cancer.
An improved colposcopic index for differentiating benign papillomaviral infections from high-grade cervical intraepithelial neoplasia. Am J Obstet Gynecol 1985; 153:611-8.
Detection of the most dangerous HPV-16 and HPV-18 types predicted high-grade cervical intraepithelial neoplasia with 92% sensitivity compared with cytology's 53.3% (P> 0.0001), Philip E.
Recent efforts to develop consensus on cervical screening policies for young females, (1,2) defined as adolescent girls and women 20 years or younger, have focused on the extraordinarily low rate of cervical cancer in young females, (1-4) high rates of human papillomavirus (HPV) infection and transient nonprogressive cervical abnormalities, (5,6) frequent regression of high-grade cervical intraepithelial neoplasia (CIN) in young females even after histopathologic confirmation, (7-9) significant risks to childbearing outcomes associated with treatment of young females by diagnostic excisional procedures, (10-12) and the potential of primary cervical cancer prevention by HPV vaccination.
The sensitivity of the Pap test to detect high-grade cervical intraepithelial neoplasia ([greater than or equal to]CIN2) ranges from 44% to 99% and specificity from 91 % to 98%.